Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3

Frontiers in Immunology

Volumn 3, Issue NOV, 2012, Pages

  Moesta, Achim K ^a   Parham, Peter ^b  

^a AMGEN INC   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Disease association; Killer cell immunoglobulin like receptor; Killer cells; Natural; Receptor ligand interaction; Structure function relationship

Indexed keywords

EID: 84874233909     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2012.00336     Document Type: Review

References (116)

1. Abi-Rached, L., Jobin, M. J., Kulkarni, S., Mcwhinnie, A., Dalva, K., Gragert, L., et al. (2011). The shaping of modern human immune systems by multiregional admixture with archaic humans. Science 334, 89-94.
2. Abi-Rached, L., Moesta, A. K., Rajalingam, R., Guethlein, L. A., and Parham, P. (2010). Human-specific evolution and adaptation led to major qualitative differences in the variable receptors of human and chimpanzee natural killer cells. PLoS Genet. 6, e1001192. doi: 10.1371/journal.pgen.1001192
3. Abi-Rached, L., and Parham, P. (2005). Natural selection drives recurrent formation of activating killer cell immunoglobulin-like receptor and Ly49 from inhibitory homologues. J. Exp. Med. 201,1319-1332.
4. Alter, G., Heckerman, D., Schnei-dewind, A., Fadda, L., Kadie, C. M., Carlson, J. M., et al. (2011). HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 476, 96-100.
5. Alter, G., Martin, M. P., Teigen, N., Carr, W. H., Suscovich, T. J., Schneidewind, A., et al. (2007). Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204, 3027-3036.
6. Alter, G., Rihn, S., Streeck, H., Teigen, N., Piechocka-Trocha, A., Moss, K., et al. (2008). Ligand independent exhaustion of killer immunoglobulin-like receptor-positive CD8+ T cells in human immunodeficiency virus type 1 infection. J. Virol. 82, 9668-9677.
7. Andersson, S., Fauriat, C., Malmberg, J. A., Ljunggren, H. G., and Malmberg, K. J. (2009). KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 114, 95-104.
8. Anfossi, N., Andre, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., et al. (2006). Human NK cell education by inhibitory receptors for MHC class I. Immunity 25, 331-342.
9. Apps, R., Murphy, S. P., Fernando, R., Gardner, L., Ahad, T., and Moffett, A. (2009). Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies. Immunology 127, 26-39.
10. Barber, L. D., Percival, L., Valiante, N. M., Chen, L., Lee, C., Gumperz, J. E., et al. (1996). The inter-locus recombinant HLA-B*4601 has high selectivity in peptide binding and functions characteristic of HLA-C. J. Exp. Med. 184, 735-740.
11. Bari, R., Bell, T., Leung, W. H., Vong, Q. P., Chan, W. K., Das Gupta, N., et al. (2009). Significant functional heterogeneity among KIR2DL1 alleles and a pivotal role of arginine 245. Blood 114,5182-5190.
12. Biassoni, R., Pessino, A., Malaspina, A., Cantoni, C., Bottino, C., Sivori, S., et al. (1997). Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur. J. Immunol. 27, 3095-3099.
13. Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P., and Salazar-Mather, T. P. (1999). Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17, 189-220.
14. Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E., and Brooks, A. G. (1998). Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis. J. Exp. Med. 187, 813-818.
15. Boyington, J. C., Brooks, A. G., and Sun, P. D. (2001). Structure of killer cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol. Rev. 181, 66-78.
16. Boyington, J. C., Motyka, S. A., Schuck, P., Brooks, A. G., and Sun, P. D. (2000). Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 405, 537-543.
17. Braud, V. M., Allan, D. S., O'Callaghan, C. A., Soderstrom, K., D'Andrea, A., Ogg, G. S., et al. (1998). HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391, 795-799.
18. Chen, C., Busson, M., Rocha, V., Appert, M. L., Lepage, V., Dulphy, N., et al. (2006). Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 38, 437-444.
19. Chewning, J. H., Gudme, C. N., Hsu, K. C., Selvakumar, A., and Dupont, B. (2007). KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR ligand group in vitro. J. Immunol. 179, 854-868.
20. Colantonio, A. D., Bimber, B. N., Neidermyer, W. J. Jr., Reeves, R. K., Alter, G., Altfeld, M., et al. (2011). KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif. PLoS Pathog. 7, e1001316. doi: 10.1371/journal.ppat.1001316
21. Colonna, M., Borsellino, G., Falco, M., Ferrara, G. B., and Strominger, J. L. (1993). HLA-C is the inhibitory lig and that determines dominant resistance to lysis by NK1 and NK2-specific natural killer cells. Proc. Natl. Acad. Sci. U.S.A. 90, 12000-12004.
22. Cooley, S., Trachtenberg, E., Berge-mann, T. L., Saeteurn, K., Klein, J., Le, C. T., et al. (2009). Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 113,726-732.
23. Cooley, S., Weisdorf, D. J., Guethlein, L. A., Klein, J. P., Wang, T., Le, C. T., et al. (2010). Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 116, 2411-2419.
24. Cooley, S., Xiao, F., Pitt, M., Glea-son, M., McCullar, V., Bergemann, T. L., et al. (2007). A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110, 578-586.
25. Davies, G. E., Locke, S. M., Wright, P. W., Li, H., Hanson, R. J., Miller, J. S., et al. (2007). Identification of bidirectional promoters in the human KIR genes. Genes Immun. 8,245-253.
26. Diaz-Pena, R., Blanco-Gelaz, M. A., and Lopez-Larrea, C. (2009). KIR genes and their role in spondy-loarthropathies. Adv. Exp. Med. Biol. 649,286-299.
27. Fadda, L., Borhis, G., Ahmed, P., Cheent, K., Pageon, S. V., Cazaly, A., et al. (2010). Peptide antagonism as a mechanism for NK cell activation. Proc. Natl. Acad. Sci. U.S.A. 107, 10160-10165.
28. Fan, Q. R., Long, E. O., and Wiley, D. C. (2001). Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat. Immunol. 2,452-460.
29. Fan, Q. R., Mosyak, L., Winter, C. C., Wagtmann, N., Long, E. O., and Wiley, D. C. (1997). Structure of the inhibitory receptor for human natural killer cells resembles haematopoietic receptors. Nature 389,96-100.
30. Fauriat, C., Andersson, S., Bjorklund, A. T., Carlsten, M., Schaffer, M., Bjorkstrom, N. K., et al. (2008). Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype. J. Immunol. 181, 6010-6019.
31. Fauriat, C., Ivarsson, M. A., Ljung-gren, H. G., Malmberg, K. J., and Michaelsson, J. (2010). Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 115, 1166-1174.
32. Foley, B., De Santis, D., Lathbury, L., Christiansen, F., and Witt, C. (2008). KIR2DS1-mediated activation overrides NKG2A-mediated inhibition in HLA-C C2-negative individuals. Int. Immunol. 20, 555-563.
33. Freud, A. G., Yokohama, A., Becknell, B., Lee, M. T., Mao, H. C., Ferketich, A. K., et al. (2006). Evidence for discrete stages of human natural killer cell differentiation in vivo. J. Exp. Med. 203, 1033-1043.
34. Fusco, C., Guerini, F. R., Nocera, G., Ventrella, G., Caputo, D., Valentino, M. A., et al. (2010). KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J. Neuroimmunol. 229, 232-237.
35. Gendzekhadze, K., Norman, P. J., Abi-Rached, L., Graef, T., Moesta, A. K., Layrisse, Z., et al. (2009). Co-evolution of KIR2DL3 with HLA-C in a human population retaining minimal essential diversity of KIR and HLA class I ligands. Proc. Natl Acad. Sci. U.S.A. 106, 18692-18697.
36. Graef, T., Moesta, A. K., Norman, P. J., Abi-Rached, L., Vago, L., Older Aguilar, A. M., et al. (2009).KIR2DS4 is a product of gene conversion with KIR3DL2 that introduced specificity for HLA-A* 11 while diminishing avidity for HLA-C. J. Exp. Med. 206,2557-2572.
37. Grzywacz, B., Kataria, N., Sikora, M., Oostendorp, R. A., Dzierzak, E. A., Blazar, B. R., et al. (2006). Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108, 3824-3833.
38. Hadaya, K., De Rham, C., Bande-lier, C., Ferrari-Lacraz, S., Jendly, S., Berney, T., et al. (2008). Natural killer cell receptor repertoire and their ligands, and the risk of CMV infection after kidney transplantation. Am. J. Transplant. 8, 2674-2683.
39. Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., et al. (2004). Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur. J. Immunol. 34, 1673-1679.
40. Hiby, S. E., Apps, R., Sharkey, A. M., Farrell, L. E., Gardner, L., Mulder, A., et al. (2010). Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J. Clin. Invest. 120, 4102-4110.
41. Hiby, S. E., Walker, J. J., O'Shaughnessy K. M., Redman, C. W., Carrington, M., Trowsdale, J., et al. (2004). Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200, 957-965.
42. Hilton, H. G., Vago, L., Older Aguilar, A. M., Moesta, A. K., Graef, T., Abi-Rached, L., et al. (2012). Mutation at positively selected positions in the binding site for HLA-C shows KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3. J. Immunol. 189, 1418-1430.
43. Hollenbach, J. A., Ladner, M. B., Sae-teurn, K., Taylor, K. D., Mei, L., Haritunians, T., et al. (2009). Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygos-ity and the HLA-C ligand. Immuno-genetics 61, 663-671.
44. Hou, Y. F., Zhang, Y. C., Jiao, Y. L., Wang, L. C., Li, J. F., Pan, Z. L., et al. (2010). Disparate distribution of activating and inhibitory killer cell immunoglobulin-like receptor genes in patients with systemic lupus ery-thematosus. Lupus 19, 20-26.
45. Jones, D. C., Edgar, R. S., Ahmad, T., Cummings, J. R., Jewell, D. P., Trowsdale, J., et al. (2006). Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun. 7, 576-582.
46. Khakoo, S. I., and Carrington, M. (2006). KIR and disease: a model system or system of models? Immunol. Rev. 214, 186-201.
47. Khakoo, S. I., Rajalingam, R., Shum, B. P., Weidenbach, K., Flodin, L., Muir, D. G., et al. (2000). Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans. Immunity 12, 687-698.
48. Khakoo, S. I., Thio, C. L., Martin, M. P., Brooks, C. R., Gao, X., Astemborski, J., et al. (2004). HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305, 872-874.
49. Lechler, R., and Warrens, A. (2000). HLA in Health and Disease, 2nd Edn, Waltham, MA: Academic Press, 472 p.
50. Lee, N., Llano, M., Carretero, M., Ishi-tani, A., Navarro, F., Lopez-Botet, M., et al. (1998). HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl. Acad. Sci. U.S.A. 95,5199-5204.
51. Ljunggren, H. G., and Karre, K. (1990). In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11,237-244.
52. Lowe, D. P., Cook, M. A., Bowman, S. J., and Briggs, D. C. (2009). Association of killer cell immunoglobulin-like receptors with primary Sjogren's syndrome. Rheumatology (Oxford) 48, 359-362.
53. Luszczek, W., Manczak, M., Cislo, M., Nockowski, P., Wisniewski, A., Jasek, M., et al. (2004). Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum. Immunol. 65, 758-766.
54. Maenaka, K., Juji, T., Nakayama, T., Wyer, J. R., Gao, G. F., Maenaka, T., et al. (1999a). Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histo-compatibility complex class I with distinct thermodynamic and kinetic properties.J. Biol Chem. 274,28329-28334.
55. Maenaka, K., Juji, T., Stuart, D. I., and Jones, E. Y. (1999b). Crystal structure of the human p58 killer cell inhibitory receptor (KIR2DL3) specific for HLA-Cw3-related MHC class I. Structure 7,391-398.
56. Malnati, M. S., Peruzzi, M., Parker, K. C., Biddison, W E., Ciccone, E., Moretta, A., et al. (1995). Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 267, 1016-1018.
57. Mandelboim, O., Reyburn, H. T., Sheu, E. G., Vales-Gomez, M., Davis, D. M., Pazmany, L., et al. (1997). The binding site of NK receptors on HLA-C molecules. Immunity 6, 341-350.
58. Martin, M. P., Gao, X., Lee, J. H., Nelson, G. W., Detels, R., Goedert, J. J., et al. (2002). Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31,429-434.
59. Martin, M. P., Qi, Y., Gao, X., Yamada, E., Martin, J. N., Pereyra, F., et al. (2007). Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39, 733-740.
60. Miller, J. S., and McCullar, V (2001). Human natural killer cells with poly-clonal lectin and immunoglobulin-like receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood 98, 705-713.
61. Moesta, A. K., Abi-Rached, L., Norman, P. J., and Parham, P. (2009). Chimpanzees use more varied receptors and ligands than humans for inhibitory killer cell Ig-like receptor recognition of the MHC-C1 and MHC-C2 epitopes. J. Immunol. 182, 3628-3637.
62. Moesta, A. K., Graef, T., Abi-Rached, L., Older Aguilar, A. M., Guethlein, L. A., and Parham, P. (2010). Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I. J. Immunol. 185, 4233-4237.
63. Moesta, A. K., Norman, P. J., Yawata, M., Yawata, N., Gleimer, M., and Parham, P. (2008). Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J. Immunol. 180, 3969-3979.
64. Momot, T., Koch, S., Hunzelmann, N., Krieg, T., Ulbricht, K., Schmidt, R. E., et al. (2004). Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 50,1561-1565.
65. Moretta, A., Vitale, M., Bottino, C., Orengo, A. M., Morelli, L., Augugliaro, R., et al. (1993). P58 molecules as putative receptors for major histocompatibility complex (MHC) class-I molecules in human natural-killer (Nk) cells anti-P58 antibodies reconstitute lysis of MHC class-I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604.
66. Nelson, G. W., Martin, M. P., Glad-man, D., Wade, J., Trowsdale, J., and Carrington, M. (2004). Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J. Immunol. 173, 4273-4276.
67. Nikitina-Zake, L., Rajalingham, R., Rumba, I., and Sanjeevi, C. B. (2004). Killer cell immunoglobulin-like receptor genes in Latvian patients with type 1 diabetes mellitus and healthy controls. Ann. N Y. Acad. Sci. 1037, 161-169.
68. Norman, P. J., Abi-Rached, L., Gendzekhadze, K., Korbel, D., Gleimer, M., Rowley, D., et al. (2007). Unusual selection on the KIR3DL1/ S1 natural killer cell receptor in Africans. Nat. Genet. 39, 1092-1099.
69. Older Aguilar, A. M., Guethlein, L. A., Adams, E. J., Abi-Rached, L., Moesta, A. K., and Parham, P. (2010). Coevolution of killer cell Ig-like receptors with HLA-C to become the major variable regulators of human NK cells. J. Immunol. 185, 4238-4251.
70. Older Aguilar, A. M., Guethlein, L. A., Hermes, M., Walter, L., and Parham, P. (2011). Rhesus macaque KIR bind human MHC class I with broad specificity and recognize HLA-C more effectively than HLA-A and HLA-B. Immunogenetics 63, 577-585.
71. Orange, J. S. (2002). Human natural killer cell deficiencies and susceptibility to infection. Microbes Infect. 4, 1545-1558.
72. Parham, P. (2005). MHC class I molecules and KIRs in human history, health and survival. Nat. Rev. Immunol. 5, 201-214.
73. Pellett, F., Siannis, F., Vukin, I., Lee, P., Urowitz, M. B., and Gladman, D. D. (2007). KIRs and autoimmune disease: studies in systemic lupus ery-thematosus and sclero derma. Tissue Antigens 69(Suppl. 1), 106-108.
74. Pende, D., Marcenaro, S., Falco, M., Martini, S., Bernardo, M. E., Mon-tagna,D., et al. (2009). Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploiden-tical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 113, 3119-3129.
75. Poon, K., Montamat-Sicotte, D., Cum-berbatch, N., Mcmichael, A. J., and Callan, M. E (2005). Expression of leukocyte immunoglobulin-like receptors and natural killer receptors on virus-specific CD8+ T cells during the evolution of Epstein-Barr virus-specific immune responses in vivo. Viral Immunol. 18, 513-522.
76. Pyo, C. W., Guethlein, L. A., Vu, Q., Wang, R., Abi-Rached, L., Norman, P. J., et al. (2010). Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS ONE 5, e15115. doi: 10.1371/jour-nal.pone.0015115
77. Rajagopalan, S., and Long, E. O. (1997). The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J. Exp. Med. 185, 1523-1528.
78. Rajagopalan, S., and Long, E. O. (2010). Antagonizing inhibition gets NK cells going. Proc. Natl. Acad. Sci. U.S.A. 107, 10333-10334.
79. Ramos-Lopez, E., Scholten, F., Aminkeng, F., Wild, C., Kalhes, H., Seidl, C., et al. (2009). Association of KIR2DL2 polymorphism rs2756923 with type 1 diabetes and preliminary evidence for lack of inhibition through HLA-C 1 lig-and binding. Tissue Antigens 73, 599-603.
80. Reveille, J. D. (2011). The genetic basis of spondyloarthritis. Ann. Rheum. Dis. 70(Suppl. 1), i44-i50.
81. Robinson, J., Mistry, K., Mcwilliam, H., Lopez, R., and Marsh, S. G. (2010). IPD -the Immuno Polymorphism Database. Nucleic Acids Res. 38,D863-869.
82. Robinson, J., Mistry, K., Mcwilliam, H., Lopez, R., Parham, P., and Marsh, S. G. (2011). The IMGT/HLA database. Nucleic Acids Res. 39, D1171-D1176.
83. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W D., Tosti, A., et al. (2002). Effectiveness of donor natural killer cell alloreac-tivity in mismatched hematopoietic transplants. Science 295, 2097-2100.
84. Saulquin, X., Gastinel, L. N., and Vivier, E. (2003). Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j). J. Exp. Med. 197, 933-938.
85. Schonberg, K., Sribar, M., Enczmann, J., Fischer, J. C., and Uhrberg, M. (2011). Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 117, 98-107.
86. Seich Al Basatena, N. K., Macna-mara, A., Vine, A. M., Thio, C. L., Astemborski, J., Usuku, K., et al. (2011). KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection. PLoS Pathog. 7, e1002270. doi: 10.1371/journal.ppat.1002270
87. Sharkey, A. M., Gardner, L., Hiby, S., Farrell, L., Apps, R., Masters, L., et al. (2008). Killer Ig-like receptor expression in uterine NK cells is biased toward recognition of HLA-C and alters with gestational age. J. Immunol. 181, 39-46.
88. Shastry, A., Sedimbi, S. K., Rajalingam, R., Nikitina-Zake, L., Rumba, I., Wigzell, H., et al. (2008). Combination of KIR 2DL2 and HLA-C 1 (Asn 80) confers susceptibility to type 1 diabetes in Latvians. Int. J. Immuno-genet. 35, 439-446.
89. Snyder, G. A., Brooks, A. G., and Sun, P. D. (1999). Crystal structure of the HLA-Cw3 allotype-specific killer cell inhibitory receptor KIR2DL2. Proc. Natl. Acad. Sci. U.S.A. 96, 3864-3869.
90. Stern, M., Elsasser, H., Honger, G., Steiger, J., Schaub, S., and Hess, C. (2008). The number of activating KIR genes inversely correlates with the rate of CMV infection/reactivation in kidney transplant recipients. Am. J. Transplant. 8,1312-1317.
91. Stewart, C. A., Laugier-Anfossi, F., Vely, F., Saulquin, X., Riedmuller, J., Tisserant, A., et al. (2005). Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc. Natl. Acad. Sci. U.S.A. 102, 13224-13229.
92. Stulberg, M. J., Wright, P. W., Dang, H., Hanson, R. J., Miller, J. S., and Anderson, S. K. (2007). Identification of distal KIR promoters and transcripts. Genes Immun. 8, 124-130.
93. Sun, J. Y., Dagis, A., Gaidulis, L., Miller, M. M., Rodriguez, R., Parker, P., et al. (2007). Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients. Biol. Blood Marrow Transplant. 13, 197-205.
94. Suzuki, Y., Hamamoto, Y., Oga-sawara, Y., Ishikawa, K., Yoshikawa, Y., Sasazuki, T., et al. (2004). Genetic polymorphisms of killer cell immunoglobulin-like receptors are associated with susceptibility to psoriasis vulgaris. J. Invest. Dermatol. 122, 1133-1136.
95. Thomas, R., Apps, R., Qi, Y., Gao, X., Male, V., O'Huigin, C., et al. (2009). HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat. Genet. 41, 1290-1294.
96. Trowsdale, J. (2001). Genetic and functional relationships between MHC and NK receptor genes. Immunity 15, 363-374.
97. Uhrberg, M., Parham, P., and Wernet, P. (2002). Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 54, 221-229.
98. Uhrberg, M., Valiante, N. M., Shum, B. P., Shilling, H. G., Lienert-Weidenbach, K., Corliss, B., et al. (1997). Human diversity in killer cell inhibitory receptor genes. Immunity 7, 753-763.
99. Vales-Gomez, M., Reyburn, H. T., Erskine, R. A., and Strominger, J. (1998). Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc. Natl. Acad. Sci. U.S.A. 95, 14326-14331.
100. Valiante, N. M., Uhrberg, M., Shilling, H. G., Lienert-Weidenbach, K., Arnett, K. L., D'Andrea, A., et al. (1997). Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7, 739-751.
101. van Bergen, J., and Koning, F. (2010). The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR. Immunology 131, 301-309.
102. VandenBussche, C. J., Dakshanamurthy, S., Posch, P. E., and Hurley, C. K. (2006). A single polymorphism disrupts the killer Ig-like receptor 2DL2/2DL3 D1 domain. J. Immunol. 177, 5347-5357.
103. van der Slik, A. R., Koeleman, B. P., Verduijn, W., Bruining, G. J., Roep, B. O., and Giphart, M. J. (2003). KIR in type 1 diabetes: disparate distribution of activating and inhibitory natural killer cell receptors in patients versus HLA-matched control subjects. Diabetes 52, 2639-2642.
104. van der Veken, L. T., Campelo, M. D., Van Der Hoorn, M. A., Hagedoorn, R. S., Van Egmond, H. M., van Bergen, J., et al. (2009). Functional analysis of killer Ig-like receptor-expressing cytomegalovirus-specific CD8+ T cells.J. Immunol. 182, 92-101.
105. Velardi, A., Ruggeri, L., and Mancusi, A. (2012). Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant. Curr. Opin. Hematol. 19, 319-323.
106. Vilches, C., Pando, M. J., and Parham, P. (2000). Genes encoding human killer-cell Ig-like receptors with D1 and D2 extracellular domains all contain untranslated pseudoexons encoding a third Ig-like domain. Immunogenetics 51, 639-646.
107. Vilches, C., and Parham, P. (2002). KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 20, 217-251.
108. Williams, F., Meenagh, A., Sleator, C., Cook, D., Fernandez-Vina, M., Bow-cock, A. M., et al. (2005). Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum. Immunol. 66, 836-841.
109. Wilson, M. J., Torkar, M., Haude, A., Milne, S., Jones, T., Sheer, D., et al. (2000). Plasticity in the organization and sequences of human KIR/ILT gene families. Proc. Natl. Acad. Sci. U.S.A. 97, 4778-4783.
110. Winter, C. C., Gumperz, J. E., Parham, P., Long, E. O., and Wagt-mann, N. (1998). Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161, 571-577.
111. Winter, C. C., and Long, E. O. (1997). A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J. Immunol. 158, 4026-4028.
112. Yawata, M., Yawata, N., Draghi, M., Partheniou, F., Little, A. M., and Parham, P. (2008). MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 112, 2369-2380.
113. Yen, J. H., Moore, B. E., Nakajima, T., Scholl, D., Schaid, D. J., Weyand, C. M., et al. (2001). Major histocom-patibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J. Exp. Med. 193, 1159-1167.
114. Yu, J., Mao, H. C., Wei, M., Hughes, T., Zhang, J., Park, I. K., et al. (2010). CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets. Blood 115, 274-281.
115. Zaia, J. A., Sun, J. Y., Gallez-Hawkins, G. M., Thao, L., Oki, A., Lacey, S. E, et al. (2009). The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 15, 315-325.
116. Zappacosta, F., Borrego, F., Brooks, A. G., Parker, K. C., and Coligan, J. E. (1997). Peptides isolated from HLA-Cw*0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc. Natl. Acad. Sci. U.S.A. 94, 6313-6318.